Biocept has entered into an agreement with a California-based independent physician association (IPA) to provide its liquid biopsy testing services to physicians and patients in their network. Biocept's Target Selector™ offering includes the choice of individual biomarker tests or a larger liquid biopsy panel, enabling physicians to select the best approach for each patient.
"We are very pleased to become a provider for this well-respected IPA, which offers comprehensive and cutting-edge medical care to its member physicians and their patients," said Michael Nall, Biocept's President and CEO. "Now, more people in California will have access to our Target Selector™ liquid biopsy testing services, which can help physicians identify actionable biomarkers in patients diagnosed with cancer and design personalized treatment programs in order to improve outcomes. We expect to announce agreements with other value-based healthcare delivery systems as the year progresses."